The Trump administration has decided not to go forward with a proposal for Medicare and Medicaid to cover high-demand obesity ...

The decision is a setback for GLP-1 drugmakers, though it's not entirely surprising given the Trump administration’s focus on ...

Opens in a new tab or window President Donald Trump's administration has decided not to cover expensive, high-demand obesity treatments under the federal government's Medicare program. CMS said ...

More than a dozen state Medicaid programs already cover the drugs for obesity. The Associated Press Health and Science Department receives support from the Howard Hughes Medical Institute’s ...